MAIA

MAIA is a clinical-stage oncology company whose entire value rests on a single unapproved asset, ateganosine (THIO). The MD&A confirms there is no commercial product and no revenue (FY2024 and FY2025 revenue both $0.00), while the company runs a Phase 2 (THIO-101) and has now initiated a Phase 3 pivotal trial (THIO-104, up to 300 patients) plus planned 2026 Phase 2 starts in HCC, CRC and SCLC. Management plans to seek accelerated FDA approval in 2026 but explicitly warns that even accelerated status 'does not guarantee an accelerated review or marketing approval.' This is a lottery-ticket profile: everything hinges on unproven clinical data.

The balance sheet cannot support that ambition. Total assets are just $9.70M against $7.33M of liabilities, leaving only $2.38M of stockholders' equity (down 34.6% YoY) and a liabilities/equity ratio of 3.08x. Reported cash & equivalents is $0.00, current liabilities jumped 52.4% to $5.84M, and the accumulated deficit has ballooned to -$110M. Against roughly $18.8M of annual operating cash burn, the company has effectively no runway without an imminent raise — precisely the scenario the Risk Factors flag: 'we will require additional capital... if we fail to obtain necessary financing, we may not be able to complete the development.'